Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Melanoma 36Carcinoma, Renal Cell 16Prostatic Neoplasms 10Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 9Uveal Melanoma 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Leukemia, Lymphocytic, Chronic, B-Cell 7Clear-cell metastatic renal cell carcinoma 7Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11pirtobrutinib 11Gemcitabine 11Carboplatin 11glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × CTLA-4 Antigen × Clear all
NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
41 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT01729806 2018-04-11

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡